In: OncoImmunology, 2017, vol. 6, no. 6, p. e1316437
Tumor angiogenesis promotes tumor growth and metastasis. Anti-angiogenic therapy in combination with chemotherapy is used for the treatment of metastatic cancers, including breast cancer but therapeutic benefits are limited. Mobilization and accumulation of myeloid-derived suppressor cells (MDSC) during tumor progression and therapy have been implicated in metastasis formation and resistance to...
|
In: Clinical Cancer Research, 2012, vol. 18, no. 16, p. 4365-4374
Purpose: Local breast cancer relapse after breast-saving surgery and radiotherapy is associated with increased risk of distant metastasis formation. The mechanisms involved remain largely elusive. We used the well-characterized 4T1 syngeneic, orthotopic breast cancer model to identify novel mechanisms of post-radiation metastasis. Experimental Design: 4T1 cells were injected in 20 Gy...
|
In: Molecular Oncology, 2015, vol. 9, no. 8, p. 1510–1527
Radiotherapy is a standard treatment after conservative breast cancer surgery. However, cancers relapsing within a previously irradiated area have an increased probability to metastasize. The mechanisms responsible for this aggressiveness remain unclear. Here, we used the clinically relevant 4T1 breast cancer model mimicking aggressive local relapse after radiotherapy to identify differences...
|
In: Clinical Cancer Research, 2012, vol. 18, no. 19, p. 5196-5202
Radiotherapy is a well-established therapeutic modality in oncology. It provides survival benefits in several different cancer types. However, cancers relapsing after radiotherapy often develop into more aggressive conditions, which are difficult to treat and are associated with poor prognosis. Cumulating experimental evidence indicates that the irradiated tumor bed contributes to such...
|
In: OncoImmunology, 2016, vol. 5, no. 11, p. e1230578
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells with the capacity to inhibit immunological responses. During cancer progression, MDSC are recruited to the tumor sites and secondary lymphoid organs, leading to the suppression of the antitumor function of NK and T cells. Here, we show that the TLR7/8 agonist resiquimod (R848) has a direct effect...
|